Guggenheim starts 'CNS gene therapy pure-play' Taysha Gene Therapies at Buy 10:59 TSHA As reported before the open, Guggenheim analyst Debjit Chattopadyaya initiated coverage of Taysha Gene Therapies with a Buy rating and $28 price target. The central nervous system, or CNS, gene therapy "pure-play" is pursuing a single vector strategy for up to 26 monogenic, neuronal diseases that potentially could be corrected via intrathecally delivered AAV9. Chattopadyaya said regulatory clarity and clinical updates from up to four programs by year-end 2022 could validate the platform, making its current $400M enterprise value an attractive entry point given the 47% year-to-date decline in the shares. > Sold off a lousy 50 shares of QURE before too much damage. Of course now the buying is happening. duh! This Taysha I didn't know it was gene therapy -
uniQure selloff on Huntington's data 'overdone,' says H.C. Wainwright 11:47 QURE After uniQure announced one-year observations on the first four patients enrolled in the lower-dose cohort of its ongoing Phase 1/2 trial evaluating AMT-130 gene therapy for Huntington's disease, H.C. Wainwright analyst Patrick Trucchio said the data support the tolerability of AMT-130. However, and "unfortunately," measurements of total and mutant HTT protein in the cerebral spinal fluid of the four patients were "highly variable and inconclusive," said Trucchio. Still, he thinks the data update was "positive" and calls the 24% decline in uniQure shares "overdone," especially given the potential for positive updates across the rest of uniQure's gene therapy platform. Trucchio reiterates a $90 price target and Buy rating on uniQure shares. reversion to mean trade > I feel crazy but I might just get right back in.
Domo so jealous of Doma Doma Holdings rises 12.0% 12:00 DOMA Doma Holdings is up 12.0%, or 59c to $5.52.
Why would the American Association of Retired People order Bolo Wrap devices? Wrap Technologies: AMRRP votes to approve funding to procure BolaWrap devices ยป 12:24 WRAP
LONG-TERM. Did I come and piss on you when your call yesterday didn't work? No. Sheesh. I trade futures minimum 3 months out. I'm now positioned 6 months out on the MES. Cut me some slack, Jack. I do not make intraday calls on the broader market, that is pointless.
Well long term.... we can pull up a chart of any index. This is common knowledge. They tend to march north. But I knew you'd say that. I almost wrote that in. Point is this one: You have a lot to learn. Market psychology tops the list.
Well, since you pissed on me, I will bring up a thorn in your side. CGC. I still intuit that if the US ever legalizes pot on the federal level, that stock will zoom north. I stand by that call. It's the only individual stock call I've ever made with conviction. *sniffs* (I did make a call on J&J some years ago about them going higher after they came out with some new wonder drug, but I did not have conviction on that one. Not sure what the price of them now is, compared to then.)